Impact of Neoadjuvant Docetaxel, Cisplatin, and 5‐Fluorouracil Therapy on Synchronous Early‐Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer

Documenti analoghi

• History of Head and Neck Cancer as a Predictor of Recurrence and Second Primary Tumors After Transoral Videolaryngoscopic Surgery in Patients With Hypopharyngeal Squamous Cell Carcinoma
  di: Mitsuhiko Katoh, et al.
  Pubblicazione: (2026)
• Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5‐Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study
  di: Ryosuke Kumanishi, et al.
  Pubblicazione: (2025)
• Long‐Term Survival of Two Versus Three Courses of Preoperative Cisplatin and Fluorouracil Plus Docetaxel for Locally Advanced Esophageal Cancer: A Multicenter Randomized Phase II Trial
  di: Takahito Sugase, et al.
  Pubblicazione: (2025)
• Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5‐Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single‐Institute Propensity Score Analysis
  di: Eiji Higaki, et al.
  Pubblicazione: (2026)
• Critical behavior of the Ising model on square-triangle tilings
  di: Koga, Akihisa, et al.
  Pubblicazione: (2024)